A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report
暂无分享,去创建一个
S. Baruchel | A. Chen | C. Ahern | P. Adamson | J. Reid | D. Yamashiro | S. Borinstein | Julie R. Park | B. Weigel | S. Blaney | A. Ingle | J. Bender
[1] R. Herbst,et al. Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] T. Choueiri,et al. The Double Edged Sword of Bleeding and Clotting from VEGF Inhibition in Renal Cancer Patients , 2012, Current Oncology Reports.
[3] E. Jonasch,et al. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] C. Ng,et al. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. , 2011, The Lancet. Oncology.
[5] M. Prados,et al. Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept , 2011, Clinical Cancer Research.
[6] J. Tabernero,et al. Intravenous (IF) Aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCC): Results of a multinational phase III trial (EFC10262-VELOUR) , 2011 .
[7] P. Carmeliet,et al. Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.
[8] A. Varan,et al. Clinical significance of serum vascular endothelial growth factor, endostatin, and leptin levels in children with lymphoma , 2010, Pediatric blood & cancer.
[9] P. Adamson,et al. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] L. Schwartz,et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Dushyant V. Sahani,et al. Biomarkers of response and resistance to antiangiogenic therapy , 2009, Nature Reviews Clinical Oncology.
[12] Helen X. Chen,et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Jianzhong Huang,et al. Sustained VEGF Blockade Results in Microenvironmental Sequestration of VEGF by Tumors and Persistent VEGF Receptor-2 Activation , 2008, Molecular Cancer Research.
[14] D. McDonald,et al. Mechanisms of adverse effects of anti-VEGF therapy for cancer , 2007, British Journal of Cancer.
[15] Napoleone Ferrara,et al. Angiogenesis as a therapeutic target , 2005, Nature.
[16] National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents , 2004, Pediatrics.
[17] Isabel Rey Madeira,et al. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. , 2004, Pediatrics.
[18] B. Rosner,et al. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents , 2004 .
[19] Jianzhong Huang,et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[20] G. Yancopoulos,et al. VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[21] Eugene S. Kim,et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[22] A. Goldhirsch,et al. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. , 2001, Blood.
[23] Lothar Schweigerer,et al. Quantification of angiogenesis stimulators in children with solid malignancies , 2001, International journal of cancer.
[24] G. Sledge,et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] N. Kanamura,et al. Effects of oral care on perioperative pediatric cancer patients , 2019, Dental, Oral and Maxillofacial Research.
[26] P. Radice,et al. Unclassified variants in BRCA genes: guidelines for interpretation. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] G. Yancopoulos,et al. Inaugural Article: VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade , 2007 .
[28] Tracy T Batchelor,et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.
[29] Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) , 2003 .